Atossa Therapeutics issued a press release on March 25, 2026, announcing fourth quarter and full year 2025 financial results, with total operating expenses of $37.1 million for the year ended December 31, 2025, up $9.5 million from $27.6 million in 2024, primarily due to increased R&D on (Z)-endoxifen trials. The company highlighted FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in DMD and management team additions.
Key takeaways
Total operating expenses $37.1 million for year ended December 31, 2025, increase of $9.5 million from $27.6 million in 2024.
R&D expenses $21.185 million in 2025, up 50% or $7.068 million from $14.117 million in 2024 due to (Z)-endoxifen trials.
G&A expenses $15.956 million in 2025, up 18% or $2.452 million from $13.504 million in 2024.
FDA granted Rare Pediatric Disease Designation for (Z)-endoxifen in DMD in December 2025.
FDA granted Orphan Drug Designation for (Z)-endoxifen in DMD in January 2026.
Added Kathy Puyana Theall, M.D. as Medical Director - Breast Oncology and Adebola Giwa, M.D. as Medical Director - Rare Diseases.
Interest income $2.4 million in 2025, decrease of $1.7 million from prior year.